Key Metrics
10.32
Heat Index-
Impact LevelMedium
-
Scope LevelNational
-
Last Update2025-08-27
Key Impacts
Positive Impacts (3)
Negative Impacts (4)
Event Overview
Innovative drug development and clinical validation processes highlight advances in biopharmaceutical research targeting autoimmune-related kidney diseases. Competitive progress in the pharmaceutical landscape is illustrated by milestone achievements in trials designed to address unmet medical needs. Regulatory and market implications arise as first-in-class biologics demonstrate significant efficacy, paving the way for potential new therapies and intensifying commercialization and patient access considerations.
Collect Records
RemeGen's Telitacicept Reaches Primary Endpoint in Phase III IgA Nephropathy Trial in China
RemeGen announced that its independently developed, first-in-class BLyS/APRIL dual-target fusion protein drug Telitacicept (brand name: Tai'ai) met the primary endpoint in the A stage of a Phase III clinical trial for the treatment of IgA nephropathy (IgAN) in China. Telitacicept was administered at a dose of 240 mg by subcutaneous injection once per week. Analysis of the A stage showed that, compared to the control group, patients in the Telitacicept group had a 55% reduction in 24-hour urine protein-to-creatinine ratio (UPCR) at week 39 of treatment (P<0.0001), and demonstrated good tolerability and safety.